Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Active Biotech

- PMLiVE

US charges Teva for generic drug price-fixing plot

Company maintains it has not committed any wrongdoing

- PMLiVE

J&J aims for US approval of MS drug ponesimod

Files application with FDA in relapsing form of the disease

- PMLiVE

Teva’s weak pipeline hit by Tourette’s drug trial failure

Drug wasn't able to improve on placebo

The role of brain health in treating MS

Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health,...

Blue Latitude Health

Diagnosing MS: are we getting it right?

Multi-award-winning patient advocate, Trishna Bharadia, walks through the complications involved with an MS diagnosis, including the challenges for healthcare systems and a handful of insightful patient stories.

Blue Latitude Health

Severe Asthma Patient Story

Streaming Well

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Teva’s migraine injection approved in Europe

Third anti-CGRP treatment to hit the market

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

Celgene building

Celgene hopes for second time lucky for ozanimod FDA filing

One of six key drugs for BMS-Celgene merger

Biogen Idec building

FDA starts review of Biogen’s Tecfidera follow-up for MS

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links